

1 **Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso:**
2 **interim results of a double-blind, randomised, controlled phase 2b trial in children**

3
4 Hamtandi M. Natama^{1,*}, Jo Salkeld^{2,3,4,*}, Athanase Somé¹, Seyi Soremekun⁵, Salou Diallo¹, Ousmane
5 Traoré¹, Toussaint Rouamba¹, Florence Ouédraogo¹, Edouard Ouédraogo¹, K. Carine Sonia Daboné¹,
6 Nadine A. Koné¹, Z. Michael John Compaoré¹, Miguel Kafando¹, Massa dit Achille Bonko¹, Fabé
7 Konaté¹, Hermann Sorgho¹, Carolyn M. Nielsen^{2,3}, Dimitra Pipini^{2,3}, Ababacar Diouf⁶, Lloyd D. W.
8 King^{2,3}, Umesh Shaligram⁷, Carole A. Long⁶, Jee-Sun Cho^{2,3,4}, Alison M. Lawrie^{4,8}, Katherine Skinner^{2,3},
9 Rachel Roberts^{2,3,4}, Kazutoyo Miura⁶, John Bradley⁵, Sarah E. Silk^{2,3}, Simon J. Draper^{2,3,8,†}, Halidou
10 Tinto^{1,†}, and Angela M. Minassian^{2,3,4,8,†}.

11
12 ¹ Unité de Recherche Clinique de Nanoro, Institut de Recherche en Sciences de la Santé, Nanoro, Burkina Faso.

13 ² Department of Biochemistry, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford, OX1 3QU, UK.

14 ³ Kavli Institute for Nanoscience Discovery, Dorothy Crowfoot Hodgkin Building, University of Oxford, Oxford,
15 OX1 3QU, UK.

16 ⁴ Centre for Clinical Vaccinology and Tropical Medicine, Jenner Institute, University of Oxford, Old Road Campus,
17 Oxford, OX3 7LE, UK.

18 ⁵ London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK.

19 ⁶ Laboratory of Malaria and Vector Research, NIAID/NIH, Rockville, MD 20852, USA.

20 ⁷ Serum Institute of India Pvt. Ltd., Pune, India.

21 ⁸ NIHR Oxford Biomedical Research Centre, Oxford, UK.

22 * Joint first authors

23 † Joint senior authors

24

25 Correspondence to: Angela M. Minassian, Department of Biochemistry, University of Oxford, Oxford,

26 OX1 3QU, UK ; angela.minassian@bioch.ox.ac.uk

27 **Abstract**

28 **Background**

29 Two pre-erythrocytic vaccines (R21/Matrix-M and RTS,S/AS01) are now approved for *P. falciparum*
30 malaria. However, neither induces blood-stage immunity against parasites that breakthrough from the
31 liver. RH5.1/Matrix-M, a blood-stage *P. falciparum* malaria vaccine candidate, was highly immunogenic
32 in Tanzanian adults and children. We therefore assessed the safety and efficacy of RH5.1/Matrix-M in
33 Burkinabe children.

34 **Methods**

35 In this double-blind, randomised, controlled phase 2b trial, RH5.1/Matrix-M was given to children aged
36 5-17 months in Nanoro, Burkina Faso – a seasonal malaria transmission setting. Children received either
37 three intramuscular vaccinations with 10 µg RH5.1 protein with 50 µg Matrix-M adjuvant or three doses
38 of rabies control vaccine, Rabivax-S, given either in a delayed third dose (0-1-5-month) regimen (first
39 cohort) or a 0-1-2-month regimen (second cohort). Vaccinations were completed part-way through the
40 malaria season. Children were randomly assigned 2:1 within each cohort to receive RH5.1/Matrix-M or
41 Rabivax-S. Participants were assigned according to a random allocation list generated by an independent
42 statistician using block randomisation with variable block sizes. Participants, their families, and the study
43 teams were masked to group allocation; only pharmacists who prepared the vaccines were unmasked.
44 Vaccine safety, immunogenicity, and efficacy were evaluated. Co-primary objectives assessed were: i)
45 safety and reactogenicity of RH5.1/Matrix-M, and ii) protective efficacy of RH5.1/Matrix-M against
46 clinical malaria from 14 days to 6 months post-third vaccination in the per-protocol population. This trial
47 is registered with ClinicalTrials.gov (NCT05790889).

48 **Findings**

49 From 6th to 13th April and 3rd to 7th July 2023, 412 children aged 5-17 months were screened, and 51 were
50 excluded. A total of 361 children were enrolled in this study. In the first cohort, 119 were assigned to the
51 RH5.1/Matrix-M delayed third dose group, and 62 to the equivalent rabies control group. The second

52 cohort included 120 children in the monthly RH5.1/Matrix-M group and 60 in the equivalent rabies
53 control group. The final vaccination was administered to all groups from 4th to 21st September 2023.
54 RH5.1/Matrix-M in both cohorts had a favourable safety profile and was well tolerated. Most adverse
55 events were mild, with the most common being local swelling and fever. No serious adverse events were
56 reported. A Cox regression model was used to analyse the primary endpoint of time to first episode of
57 clinical malaria, according to the primary case definition, within 14 days to 6 months post-third
58 vaccination. Comparing the RH5.1/Matrix-M delayed third dose regimen with the pooled control groups
59 resulted in vaccine efficacy of 55% (95% CI 20-75%; p=0.0071). The same analysis showed a vaccine
60 efficacy of 40% (95% CI -3-65%; p=0.066) when comparing the monthly regimen with the pooled
61 control groups. Participants vaccinated with RH5.1/Matrix-M in both cohorts showed high concentrations
62 of anti-RH5.1 serum IgG antibodies 14 days post-third vaccination, and the purified IgG showed high
63 levels of *in vitro* growth inhibition activity (GIA) against *P. falciparum*; these responses were higher in
64 RH5.1/Matrix-M vaccinees who received the delayed third dose, as opposed to monthly, regimen.

65 **Interpretation**

66 RH5.1/Matrix-M appears safe and highly immunogenic in African children and shows promising efficacy
67 against clinical malaria when given in a delayed third dose regimen. This trial remains ongoing to further
68 monitor efficacy over time.

69 **Funding**

70 The European and Developing Countries Clinical Trials Partnership; the UK Medical Research Council;
71 the National Institute for Health and Care Research Oxford Biomedical Research Centre; the Division of
72 Intramural Research, National Institute of Allergy and Infectious Diseases; the US Agency for
73 International Development; and the Wellcome Trust.

74 **Introduction**

75 Malaria caused by the *Plasmodium falciparum* parasite continues to exert a heavy disease burden across
76 sub-Saharan Africa.¹ However, two first-generation partially-effective pre-erythrocytic vaccines
77 (RTS,S/AS01 and R21/Matrix-M) are now recommended for malaria prevention in children using a 4-
78 dose schedule from around 5 months of age. These two vaccines are similar in design and target the liver-
79 invasive sporozoite.^{2,3} However when this immunity fails or wanes over time, and sporozoites infect the
80 liver, blood-stage infection ensues with risk of clinical disease. Vaccination against the blood-stage
81 merozoite would thus provide a second line of defence. However, development of an effective blood-
82 stage vaccine has proved challenging,⁴ with all prior phase 2b field efficacy trials reporting either no or
83 minimal efficacy, or evidence of strain-specific efficacy linked to target antigen polymorphism.⁵⁻⁹
84
85 Identification of the reticulocyte-binding protein homologue 5 (RH5) as a vaccine target,¹⁰ has since
86 transformed the blood-stage *P. falciparum* vaccine field. This merozoite protein forms an essential
87 interaction with basigin/CD147 on the human red blood cell during invasion¹¹ and, unlike previous
88 antigen targets, is almost completely conserved, likely explaining the human-species tropism of this
89 parasite.¹² We have previously demonstrated high-level efficacy of RH5-based vaccination in non-human
90 primates (NHPs)¹³ and a significant reduction in parasite growth rate in UK adult vaccinees post-
91 challenge.¹⁴ In both the NHP and human studies we observed a strong correlation between *in vivo*
92 reduction of parasite growth and *in vitro* growth inhibition activity (GIA),^{13,14} since validated as a
93 mechanistic immune correlate in NHPs.¹⁵ We have also reported promising safety and reactogenicity data
94 from four phase 1a/b trials of RH5-based vaccine candidates in 193 adults, children and infants in the UK
95 and Tanzania.^{14,16-18} Notably, the RH5.1 protein¹⁹ with Matrix-M adjuvant, in 5-17 month-old Tanzanian
96 children, gave the highest levels of human vaccine-induced GIA ever reported, exceeding the protective
97 threshold identified in the NHP model.^{13,18} We therefore initiated a phase 2b trial (called “VAC091”) of

Natama HM *et al.*

- 98 this vaccine candidate in children aged 5-17 months in Nanoro, a seasonal malaria transmission setting in
- 99 Burkina Faso, to assess its protective efficacy against clinical malaria.

100 **Methods**

101 **Study design and participants**

102 VAC091 is a double-blind, randomised, controlled phase 2b trial conducted by the Institut de Recherche
103 en Sciences de la Santé at the Clinical Research Unit of Nanoro, Burkina Faso and sponsored by the
104 University of Oxford. Participants aged 5-17 months were recruited at the Siglé trial site, located within
105 the Nanoro Health and Demographic Surveillance System (HDSS) catchment area. This covers 24
106 villages, with a population of over 63,000 inhabitants. Nanoro is an area where malaria transmission
107 occurs throughout the year, but with a marked peak during the rainy season (June to November).

108
109 Eligible participants were recruited into four groups (figure 1; appendix p 24). Groups 1 and 2 (first
110 cohort) received the delayed third-dose (0-1-5-month) regimen (“delayed regimen”) of rabies or
111 RH5.1/Matrix-M vaccines, respectively. Groups 3 and 4 (second cohort) received these vaccines in a
112 “monthly regimen” (0-1-2-month). The third vaccination was given simultaneously across all four groups
113 and completed part-way through the malaria season. Field workers collected data on indoor residual
114 spraying (IRS) of households, insecticide treated net (ITN) use and if the nets were adequate (according
115 to if holes were present), and number of doses and months of seasonal malaria chemoprevention (SMC)
116 taken by the participant during the malaria transmission season.

117
118 After community sensitisation, a list of eligible children was drawn from the HDSS database, and parents
119 or legally authorised guardians who expressed interest were invited to screening visits. Prior to the
120 recruitment, parents or guardians of participants provided written or thumb-printed consent, which was
121 verbally checked at each study visit. Inclusion criteria specified that participants should be aged 5-17
122 months at enrolment and aim to be living in the study area for the whole trial duration. Exclusion criteria
123 included significant co-morbidities and participation in other malaria intervention studies and clinical
124 trials. Further details are given in the appendix (pp 8-9).

125 The trial was approved by the National Ethical Committee of the Ministry of Health (Comité d’Ethique
126 pour la Recherche en Santé, reference number 2022-12-256), and the national regulatory authority,
127 Agence National de Régulation Pharmaceutique (reference 2023/0208/MSHP/SG/ANRP/DHEC/MIK), in
128 Burkina Faso. Ethical approval was granted in the UK by the Oxford Tropical Research Ethics Committee
129 (reference 3-23). This study is registered with ClinicalTrials.gov, NCT05790889.

130

131 **Randomisation and masking**

132 Children aged 5-17 months were randomly assigned (1:2) to Groups 1 and 2 (delayed third-dose regimen)
133 in the first cohort and similarly to Groups 3 and 4 (monthly regimen) in the second cohort. A statistician
134 generated a random allocation list, using block randomisation with variable block sizes, and prepared and
135 sealed the envelopes using this list, which was then given to the pharmacist to assign to participants. Both
136 malaria and control vaccines were prepared by the pharmacist using the same type of syringe, and the
137 contents of the syringe were covered with an opaque label. The trial was double-blinded; participants,
138 their families, the central and local study teams and laboratory teams, were masked to group allocation.
139 Only the pharmacists preparing the vaccines and statisticians were unmasked to group allocation.

140

141 **Procedures**

142 The RH5.1 soluble protein was originally produced according to Good Manufacturing Practice (GMP) by
143 the Clinical Biomanufacturing Facility in Oxford, UK.¹⁹ A second batch was filled in 2021 under GMP by
144 a Contract Manufacturing Organisation in the UK and was used in this trial. A 10µg dose of RH5.1
145 protein was mixed with 50µg Matrix-M, a potent, saponin-based adjuvant manufactured by Novavax AB
146 (Uppsala, Sweden) and the Serum Institute of India Pvt. Ltd. (SIPL), immediately before administration.
147 A rabies vaccine (Rabivax-S), manufactured by SIPL, was the control vaccine. All vaccines were
148 administered intramuscularly into the thigh.

149

150 On the day of enrolment, a blood film was performed to check for *Plasmodium* spp. parasites. In the
151 absence of a fever $\geq 37.5^{\circ}\text{C}$ and/or history of fever within the last 24 hours, participants proceeded to
152 vaccination, but if then found to be film-positive, they received treatment for malaria in accordance with
153 national guidelines. For each subsequent vaccination, participants were tested for malaria if they had a
154 fever of $\geq 37.5^{\circ}\text{C}$ and/or history of fever within the last 24 hours. If their blood film was positive, they
155 were treated for malaria before being vaccinated upon recovery. After each vaccination, local and
156 systemic solicited adverse events (AEs) were collected for 7 days. Unsolicited AEs were collected for 28
157 days after vaccinations and classified according to MedDRA (version 27.0). Severity and causality of
158 AEs were assessed using standardised methods (appendix pp 10-12, 25-26) and followed up until
159 resolution. Safety laboratory values were measured at 14 days post-second vaccination, day of third
160 vaccination (Groups 1 and 2 only) and two and six months post-third vaccination to look for deviations
161 from baseline. Serious adverse events (SAEs) are being recorded for the whole duration of the study. A
162 Data Safety Monitoring Board (DSMB) review was held after the first vaccination of the first 100
163 participants.

164
165 Parents of participants were advised to attend the trial site or community health centres if their child had
166 any illness or fever, for review and assessment for malaria. After the third vaccination, participants were
167 also visited by field workers approximately every 30 days until 6 months after the third vaccination and a
168 blood spot was taken for parasite quantification and genotyping. If they had a temperature of $\geq 37.5^{\circ}\text{C}$
169 and/or history of fever within the last 24 hours, blood sampling was also performed for blood film
170 microscopy to detect *Plasmodium* spp.

171
172 Anti-RH5.1 serum total IgG responses were measured by ELISA against full-length RH5 protein
173 (RH5.1), using standardised methodology as previously described.¹⁸ Standardised GIA assays were

174 performed by the GIA Reference Center, NIH, USA, using previously described methodology²⁰ (appendix
175 p 22-23).

176

177 **Outcomes**

178 The co-primary objectives assessed were: i) safety and reactogenicity of RH5.1/Matrix-M, and ii)
179 protective efficacy of RH5.1/Matrix-M against clinical malaria from 14 days to 6 months post-third
180 vaccination. The primary case definition of clinical malaria was presence of an axillary temperature of
181 $\geq 37.5^{\circ}\text{C}$ and/or history of fever in the past 24 hours, and *P. falciparum* asexual parasite density >5000
182 parasites per μL . Secondary case definitions were presence of an axillary temperature of $\geq 37.5^{\circ}\text{C}$ and/or
183 history of fever during the last 24 hours, and i) *P. falciparum* parasite density of >0 parasites per μL ; or ii)
184 parasite density of $>20,000$ parasites per μL . Post-hoc analyses assessed additional case definitions with
185 parasite densities of $>50,000$ and $>100,000$ parasites per μL . Secondary objectives assessed i) protective
186 efficacy of RH5.1/Matrix-M against clinical malaria from 14 days to 3 months post-third vaccination; ii)
187 protective efficacy of RH5.1/Matrix-M against prevalent moderate or severe anaemia at 6 months post-
188 third vaccination; and iii) the humoral immunogenicity of RH5.1/Matrix-M. Analysis of other pre-
189 specified secondary objectives regarding the primary vaccination series remain in progress and will be
190 reported after the end of the trial (appendix pp 12-15).

191

192 **Statistical analysis**

193 It was estimated that 104 children per arm would give 90% power to detect a 50% vaccine efficacy in
194 either Group 2 or 4 compared to the pooled controls (Groups 1 and 3) if there were 1.2 episodes of
195 clinical malaria per child in the first 6 months of follow up in the control arm (appendix p 7). The rate of
196 1.2 events per child comes from a study previously conducted in the same area.³ 120 children per arm
197 were recruited to allow for 15% loss to follow-up.

198

199 For the co-primary endpoint of vaccine safety and reactogenicity, odds ratios comparing the proportion of
200 doses that resulted in solicited AEs were calculated using logistic regression. For the co-primary endpoint
201 of vaccine efficacy, Cox regression models were used to analyse time to first episode of clinical malaria
202 (as per the primary case definition) within 6 months post-third vaccination. Follow up time started 14
203 days post-third vaccination. Vaccine efficacy (VE) was calculated as 1 minus the hazard ratio (HR). The
204 secondary and additional case definitions of clinical malaria were analysed in the same way. A secondary
205 analysis of VE against all clinical malaria episodes was also carried out, using Cox regression models
206 with a robust standard error to account for multiple episodes. Episodes occurring within 14 days of a
207 previous episode were classed as the same event. For participants without an episode of clinical malaria,
208 their time was censored at the date of their withdrawal or the date of their 6-month blood sampling
209 (noting no deaths have occurred in this trial). A secondary analysis of time to first episode of clinical
210 malaria (analysed as per the primary endpoint) but restricted to episodes occurring within 3 months of the
211 third vaccination was also carried out. The primary comparisons were pre-specified as being between
212 Group 2 and the pooled control Groups 1 and 3, and between Group 4 and the pooled Groups 1 and 3,
213 with comparison of Groups 1 to 2 and 3 to 4 as a supplementary analysis. A secondary analysis adjusted
214 for confounding factors including total number of rounds of SMC received, ITN use (adequate or not) the
215 night before the screening visit, and age at randomisation (5-8 months, 9-12 months, or 13-17 months).
216 Event rates of malaria are also reported here, but for information only.

217
218 The primary analysis of VE was based on a per-protocol population, which included all participants who
219 received three vaccinations correctly and within the pre-specified time period. Secondary analyses
220 included the intention-to-treat population of any child who received at least the first dose of vaccine and
221 remained in the site at the start of the follow-up period (2 weeks post their third dose).

222

223 Assays to measure *in vitro* *P. falciparum* GIA and serum anti-RH5.1 IgG responses were conducted on
224 blood samples taken at baseline (screening) and at day 14 post-third vaccination. GIA data were
225 expressed as percentages and compared between the combined control groups and each RH5.1/Matrix-M
226 vaccine group, and between the two RH5.1/Matrix-M vaccine groups. The measure of effect was the
227 difference in mean percentage GIA, with inference done using the bootstrap method. Serum anti-RH5.1
228 IgG concentrations measured by ELISA were log₁₀-transformed and the same between-arm comparisons
229 performed by linear regression.

230

231 All statistical analyses were performed by independent statisticians using Stata, version 18.

232

233 **Role of the funding source**

234 The funder of the study had no role in study design, data collection, data analysis, data interpretation, or
235 writing of the report.

236 **Results**

237 From 6th to 13th April 2023, 208 children aged 5-17 months were screened, and from 3rd to 7th July 2023, a
238 further 204 children aged 5-17 months were screened (figure 1). Fifty-one were excluded and 361
239 enrolled across two cohorts. In the first cohort, 119 children were allocated to receive RH5.1/Matrix-M in
240 a delayed third-dose regimen (Group 2) and 62 children allocated to rabies vaccination in the same
241 regimen (Group 1). In the second cohort, 120 children were allocated to RH5.1/Matrix-M in a monthly
242 regimen (Group 4) and 60 children allocated to receive rabies vaccination in the same regimen (Group 3).
243 The final vaccination of the primary series was administered contemporaneously across both cohorts from
244 4th to 21st September 2023. Twenty-two participants received fewer than three vaccinations, and one
245 participant in Group 3 who received three vaccinations had an interval of less than 21 days between the
246 second and third vaccine doses, so 338 participants were included in the per-protocol analysis at six
247 months post-third vaccination.

248
249 Baseline characteristics were similar across the four study groups, with the overall mean age at screening
250 of 10.5 months (SD 3.6), and 177 (52.4%) of the enrolled participants being female (appendix p 31). Of
251 the 361 participants, 290 (85.8%) slept under an adequate ITN the night before screening, and 333
252 (98.5%) received at least one round of SMC. However, only 8 (2.4%) of 361 participants lived in a house
253 which had received IRS with insecticide in the past year.

254
255 Analysis of the primary endpoint of time to first episode of clinical malaria (as per the primary case
256 definition) within 14 days to 6 months post-third vaccination, using a Cox regression model to compare
257 the RH5.1/Matrix-M delayed third dose regimen with the pooled control groups, resulted in VE of 55%
258 (95% CI 20-75%; p=0.0071); the same analysis showed a VE of 40% (95% CI -3-65%; p=0.066) when
259 comparing the monthly regimen with the pooled control groups (table 1 and figure 2A).

260

261 During this primary objective study period (within 14 days to 6 months post-third vaccination) a first
262 episode of clinical malaria occurred in 17 of 114 participants (14.9%) in the delayed RH5.1/Matrix-M
263 group (event rate 0.09/100 child days); 22 of 112 participants (19.6%) in the monthly RH5.1/Matrix-M
264 group (event rate 0.12/100 child days); and 33 of 112 participants (29.5%) in the pooled rabies control
265 groups (event rate 0.21/100 child days) (table 1). In total, 72 of 338 participants (21.3%) had at least one
266 episode of clinical malaria according to the primary case definition however, of these, 10 also had more
267 than one episode. In a secondary analysis, VE against all clinical malaria episodes up to 6 months (as per
268 the primary case definition), analysed using Cox regression models, was 56% (95% CI 24-74%;
269 $p=0.0035$) for the delayed and 40% (95% CI 1-64%; $p=0.045$) for the monthly RH5.1/Matrix-M regimen
270 (appendix pp 34-35).

271
272 As a secondary objective, we also analysed time to first episode of clinical malaria (as per the primary
273 case definition) within 14 days to 3 months post-third vaccination using a Cox regression model. Here,
274 a VE of 56% (95% CI 21-76%; $p=0.0062$) in the delayed regimen and 52% (95% CI 13-73%; $p=0.015$)
275 in the monthly regimen was observed when comparing with the pooled control groups (appendix pp 44-
276 45). Here, 65 of 338 participants (19.2%) had at least one episode of malaria according to the primary
277 case definition during this period.

278
279 We also analysed the time to first episode of clinical malaria, using a Cox regression model, according to
280 secondary case definitions of clinical malaria during the 6-month period with i) a parasitaemia >0 per μL ;
281 here VE of 44% [95% CI 8-66%; $p=0.023$] was observed in the delayed group and 8% [95% CI -44-41%;
282 $p=0.73$] in the monthly group; and ii) a parasitaemia $>20,000$ per μL ; here VE of 69% [95% CI 35-85%;
283 $p=0.0017$] was observed in the delayed group and 47% [95% CI 3-71%; $p=0.041$] in the monthly group
284 (table 1, figure 2B,C). In light of these results, additional post-hoc analyses were performed for case
285 definitions of clinical malaria with i) parasitaemia $>50,000$ per μL ; here VE of 81% [95% CI 44-94%;

286 p=0.0026] was observed in the delayed group and 90% [95% CI 58-98%; p=0.0017] in the monthly
287 group; and ii) parasitaemia >100,000 per μ L; here VE of 83% [95% CI 23-96%; p=0.021] was observed
288 in the delayed group and 91% [95% CI 33-99%; p=0.019] in the monthly group (table 1, figure 2D,E).
289 Secondary analyses of all efficacy endpoints for the intention-to-treat population showed similar results to
290 those for the per-protocol population (appendix pp 38-43, 46).

291
292 There were no SAEs, AEs of special interest (AESIs) or suspected unexpected serious adverse reactions
293 (SUSARs) reported out to 6 months post-third vaccination. There were no safety concerns raised by the
294 DSMB following review of 7 days' data after vaccination of the first 100 participants, and no further
295 safety reviews were required. Swelling was the most common local solicited AE, reported after 24/696
296 (3.4%) RH5.1/Matrix-M vaccinations, with significantly more swelling reported in the delayed
297 RH5.1/Matrix-M group compared to the combined control groups (odds ratio [OR] 11.2, 95% CI 2.6-
298 49.4, p=0.0014). The most common systemic solicited AE was fever, reported after 97/696 (13.9%)
299 RH5.1/Matrix-M vaccinations and 5/349 (1.4%) rabies vaccinations (table 2). There were significantly
300 more fevers in both the delayed (OR 14.1, 95% CI 5.3-37.1, p<0.0001) and monthly (OR 9.7, 95% CI
301 3.7-25.9, p<0.0001) RH5.1/Matrix-M vaccination groups as compared to the control groups. No
302 participants experienced febrile convulsions. The majority of solicited AEs were mild to moderate in
303 severity. Four participants (1.7%) were reported to have severe pain following RH5.1/Matrix-M
304 vaccination, compared to four (3.3%) following rabies vaccination. Three participants (1.3%) were
305 reported to have severe fever and one participant (0.4%) reported to have severe loss of appetite
306 following RH5.1/Matrix-M vaccination (appendix pp 47-48).

307
308 For unsolicited AEs, 39 MedDRA terms were assigned in the 28 days following each of the three
309 vaccinations and there were no significant differences in the number of events per group (appendix pp 49-
310 52). All were classified as unrelated to the vaccines, with the exception of a single episode of moderate

311 fever in the delayed third-dose group within 28 days of vaccination. There were no cases of severe
312 anaemia (haemoglobin <5.0g/L), no participants requiring blood transfusion, and no significant
313 differences in the frequency of moderate anaemia (haemoglobin <8.0g/L) between the groups (appendix
314 53). There were no cases of severe malaria in any participant in the 6 months post-third vaccination.
315
316 At baseline, almost all participants showed background level anti-RH5.1 serum IgG antibody responses.
317 At 14 days post-third vaccination, responses remained comparable to baseline in the combined rabies
318 vaccine control groups. In contrast, high responses were seen in the delayed regimen RH5.1/Matrix-M
319 group (geometric mean anti-RH5.1 IgG concentration 837µg/mL; inter-quartile range [IQR] 326-2200);
320 these were significantly higher as compared to the monthly regimen group (geometric mean 626µg/mL;
321 IQR 222-1455; p=0.0006) (figure 3A). *In vitro* functional anti-parasitic activity was assessed by the GIA
322 assay at a total purified IgG concentration of 2.5 mg/mL at 14 days post-third vaccination. Samples from
323 control participants showed negligible GIA (<20%), apart from three participants who had GIA of >50%.
324 Mean GIA in the delayed regimen RH5.1/Matrix-M group was 79.0% (standard deviation [SD] 14.3),
325 significantly higher than the mean GIA in the monthly group of 74.2% (SD 15.9; p=0.016) (figure 3B,
326 appendix pp 54-55).

327 **Discussion**

328 We report that the standalone blood-stage vaccine candidate RH5.1/Matrix-M, delivered in a delayed
329 third dose (0-1-5 month) regimen, shows significant efficacy of 55% (95% CI 20-75%) against clinical
330 malaria in the target population of African children over 6 months' follow-up. The vaccine was also well-
331 tolerated and no SAEs were reported out to 6-months following the third vaccination. Data now reported
332 for a total of 109 adults, 305 children and 18 infants vaccinated with RH5-based vaccines in the UK,
333 Tanzania and Burkina Faso^{14,16-18} all show similar safety and tolerability profiles, whilst Matrix-M
334 adjuvant is now licensed in vaccines for malaria and Covid-19.^{3,21} On-going phase 1/2 trials continue to
335 monitor the safety of RH5.1/Matrix-M vaccination.

336
337 Here we studied RH5.1/Matrix-M efficacy for the first time in an area of seasonal malaria transmission,
338 with vaccinations completing part-way through the malaria season. Previously published field efficacy
339 trials of *P. falciparum* blood-stage vaccine candidates, targeting a variety of antigens including AMA1,
340 MSP1, MSP2, GLURP, MSP3 and RESA, all yielded disappointing results, reporting either no or
341 minimal clinical efficacy, or in some cases evidence of strain-specific efficacy linked to target antigen
342 polymorphism.⁵⁻⁹ Given these studies were performed over the last 25 years in different settings with
343 different transmission patterns and in children of different age ranges, it is not possible to directly
344 compare with our study. However, our results demonstrate that a standalone blood-stage vaccine can
345 achieve significant efficacy against clinical malaria in 5-17 month old children, in line with the approved
346 age range for use of the pre-erythrocytic vaccines RTS,S/AS01 and R21/Matrix-M, and now enabling
347 future assessment of combination malaria vaccine strategies targeting two stages of the parasite's
348 lifecycle. Indeed, a second-generation multi-stage paediatric vaccination strategy offers hope for higher
349 and more durable efficacy against clinical malaria, especially if the pre-erythrocytic and blood-stage
350 components act additively, or even synergistically.

351 SMC was given to children in the study area as part of a programme by local health services, as per
352 national policy recommendation, but coverage was suboptimal. Our study documented SMC uptake, but
353 did not deliver any further SMC. It will be important in the future to test RH5.1/Matrix-M efficacy in
354 settings where there is no SMC, and to also determine in seasonal settings whether combination of blood-
355 stage and pre-erythrocytic vaccines can achieve a better outcome (than a pre-erythrocytic vaccine alone)
356 as indicated by studies of RTS,S/AS01 and SMC.²²

357
358 Our study was not powered to show a difference in VE between the 0-1-2 and 0-1-5-month delivery
359 regimens with RH5.1/Matrix-M. However, the VE for the 0-1-5 month regimen was higher than for the
360 0-1-2 month regimen, and this is consistent with the 0-1-5-month regimen inducing higher IgG
361 concentrations and GIA. The difference in VE was larger at 6 months than 3 months, suggesting the 0-1-
362 5-month regimen may offer more durable protection. Previous trials of RTS,S/AS01 reported improved
363 efficacy against malaria challenge in healthy US adults when using a 0-1-7-month regimen with antigen
364 and adjuvant fractionated for the delayed third dose (as opposed to 0-1-2-month dosing),²³ however, this
365 did not translate to improved field efficacy in 5-17 month old children.²⁴ In line with these observations,
366 our previous phase 1b trial data with RH5.1/Matrix-M in Tanzanian children suggested that a delayed
367 (full) third dose, as opposed to monthly dosing or a delayed fractional third dose, may induce more
368 robust and durable antibody responses.¹⁸ On-going analyses in this trial will thus continue to investigate
369 whether the delayed third dose regimen induces more durable immunity in contrast to monthly dosing.

370
371 Notably, our secondary and post-hoc analyses showed lower VE (as compared to the primary endpoint)
372 when we used the secondary clinical malaria case definition of any parasitaemia (>0 parasites/ μ L) but
373 increasingly improved efficacy when we used secondary or additional malaria case definitions with a
374 higher parasitaemia cut-off of >20,000, >50,000 or >100,000 parasites/ μ L. The delayed third dose
375 RH5.1/Matrix-M regimen showed significant efficacy against all definitions, whilst the monthly regimen

376 only reached significance at the higher cut-offs consistent with the more modest performance of this
377 regimen but nonetheless suggesting biological effect. These data appear in line with research in animal
378 vaccination and challenge models of malaria,¹³ whereby blood-stage malaria vaccines can reduce peak
379 parasitaemia. This would also not be expected to occur with pre-erythrocytic vaccines; indeed, post-hoc
380 analysis of data from the phase 3 trial of R21/Matrix-M³ showed almost identical VE for all the cut-off
381 levels of parasitaemia analysed here (Adrian Hill, personal communication). Consequently, our data
382 show that RH5.1/Matrix-M can partially protect against clinical malaria but can also reduce blood-stage
383 parasitaemia in clinical cases. This may have implications for prevention of severe or life-threatening
384 disease in the real-world setting when pre-erythrocytic- and/or blood-stage vaccine-induced immunity to
385 clinical malaria fails or wanes.

386
387 Solicited AE rates observed with RH5.1/Matrix-M compare favourably to those seen in the phase 3 trials
388 of R21/Matrix-M and RTS,S/AS01.^{2,3} Swelling at the injection site, the most common local solicited AE
389 in this trial, occurred following 4% of vaccinations with R21/Matrix-M and 10% with RTS,S/AS01, in
390 comparison to 3% with RH5.1/Matrix-M. For R21/Matrix-M and RTS,S/AS01, the most common local
391 solicited AE was pain, occurring following 19% and 12% of vaccinations respectively, in comparison to
392 3% with RH5.1/Matrix-M. Fever was the most common systemic solicited AE with all vaccines,
393 occurring following 47% of vaccinations with R21/Matrix-M and 31% with RTS,S/AS01, in comparison
394 to 14% with RH5.1/Matrix-M.

395
396 The absence of RH5 serum antibody responses at baseline or in the control groups at 14 days post-third
397 vaccination is consistent with the known sero-epidemiology and sequence conservation of RH5,
398 suggesting this antigen is not a dominant target of naturally-acquired malaria immunity.^{10,16,25} In contrast,
399 the RH5.1/Matrix-M vaccine candidate was highly immunogenic for functional anti-RH5.1 serum IgG
400 antibody across both dosing regimens, with the delayed third dose regimen showing small but significant

401 improvements in the ELISA and GIA responses (as compared to the monthly regimen) 14 days post-third
402 vaccination, in line with our data seen in Tanzanian children in the RH5.1/Matrix-M phase 1b study.¹⁸
403 The mean GIA observed in both RH5.1/Matrix-M groups, and over 80% of individual children, at this
404 timepoint also exceeded 60% GIA measured at 2.5 mg/mL total IgG (appendix p 54-55) – a threshold
405 level we previously reported as required for protection following RH5 vaccination and *P. falciparum*
406 blood-stage challenge in *Aotus* monkeys.^{13,15} These data are thus consistent with both RH5.1/Matrix-M
407 regimens showing significant efficacy against clinical malaria in the first 3 months post-third
408 vaccination. Analysis of the kinetic of both groups' immune responses beyond this peak post-vaccination
409 timepoint are ongoing, but the efficacy data after 3 months suggest that differences may be seen with
410 respect to serum antibody durability and/or the possibility for natural boosting of the vaccine-induced
411 response.

412
413 This study has limitations, including the completion of vaccine doses part-way through the malaria
414 season. It is possible that VE might be different if administered earlier, i.e. with the primary vaccination
415 series (all three doses) being completed prior to the season. Another limitation that comes from
416 administering the vaccine part-way through the malaria season is that there was insufficient follow up
417 time to observe many children having multiple episodes. It is possible that naturally-acquired immunity
418 may interact with vaccine-induced immunity, protecting children from subsequent episodes, but the
419 current analysis was unable to investigate this. Nonetheless, follow-up of the VAC091 trial is continuing
420 to determine efficacy at 12 months post-third vaccination, and to assess the durability of the vaccine-
421 induced immune response and the potential impact of natural malaria exposure. We will also administer a
422 fourth (booster) dose of vaccine at 12 months to Groups 1-4 to enable efficacy monitoring over a second
423 year of follow-up. We also limited the age range of participants in this trial to 5-17 months, to align with
424 earlier studies of RTS,S/AS01 and R21/Matrix-M. A wider age range, inclusive of younger infants and
425 older children, will be covered in future trials. We have not yet assessed RH5.1/Matrix-M delivered in an

Natama HM *et al.*

426 age-based (non-seasonal) administration schedule, or in sites with lower or higher levels of perennial
427 malaria transmission as compared to the seasonal setting in Nanoro; this will be addressed in future
428 studies. We have also not yet formally analysed our immunological datasets for correlates of protection;
429 this, along with assessment for any evidence of *P. falciparum* strain-selection in vaccinees versus
430 controls, remains the focus of ongoing work.

431 **Contributors**

432 JS, SES, SJD and AMM conceived the trial. HT was the trial principal investigator, AMM the chief
433 investigator, and SJD the senior laboratory investigator. HMN, JS, AS, SD, OT, TR, FO, EO, KCSD,
434 NAK, ZMJC, MK, MAB, FK, HS, CMN, DP, AD, CAL, KM, SES, HT and AMM contributed to the
435 implementation of the study and data collection. SS and JB analysed data and completed statistical
436 analysis. HMN, SD, JSC, AML, KS and RR performed project management. LDWK, US and KS assisted
437 with vaccine provision. HMN, JS, KM, SES, SJD, HT and AMM interpreted data, contributed to writing
438 the manuscript and have accessed and verified the data.

439

440 **Declaration of interests**

441 LDWK and SJD are named inventors on patent applications relating to RH5 malaria vaccines. AMM has
442 an immediate family member who is an inventor on patent applications relating to RH5 malaria vaccines.
443 US is an employee of Serum Institute of India Pvt. Ltd., manufacturer of R21/Matrix-M vaccine. All other
444 authors declare no competing interests.

445

446 **Data sharing**

447 Data associated with this study are present in the paper or appendix and will be available after the end of
448 the study upon reasonable request that should be directed to the corresponding author. Proposals will be
449 reviewed and approved by the Sponsor, Chief Investigator, and collaborators. After approval of a
450 proposal, data can be shared through a secure online platform after signing a data access agreement. Any
451 shared data will be de-identified.

452 **Acknowledgments**

453 We thank all the trial participants and their parents, and the independent DSMB for overseeing the trial.
454 This work was funded in part by the European and Developing Countries Clinical Trials Partnership
455 (EDCTP) Multi-Stage Malaria Vaccine Consortium (MMVC) [RIA2016V-1649-MMVC]; a Wellcome
456 Trust Translation Award [205981/Z/17/Z], the UK Medical Research Council [MR/K025554/1 and
457 MR/V038427/1, the latter UK-funded award is carried out in the frame of the Global Health EDCTP3
458 Joint Undertaking]; the National Institute for Health and Care Research (NIHR) Oxford Biomedical
459 Research Centre (BRC), the views expressed are those of the authors and not necessarily those of the
460 NHS, the NIHR, or the Department of Health; Matrix-M adjuvant and rabies vaccine was supplied by
461 SIPL; the GIA work was supported by the Division of Intramural Research, National Institute of Allergy
462 and Infectious Diseases (NIAID) and by an Interagency Agreement [AID-GH-T-15-00001] between the
463 United States Agency for International Development (USAID) Malaria Vaccine Development Program
464 (MVDP) and NIAID. The findings and conclusions are those of the authors and do not necessarily
465 represent the official position of USAID. CMN held a Wellcome Trust Sir Henry Wellcome Postdoctoral
466 Fellowship [209200/Z/17/Z]. SJD is a Jenner Investigator. All authors had full access to all the data in the
467 study and had final responsibility for the decision to submit for publication.

468 **References**

- 469 1. World Health Organization. World Malaria Report; 2023.
- 470 2. Rts SCTP. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in
471 infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. *Lancet*
472 2015; **386**(9988): 31-45.
- 473 3. Dattoo MS, Dicko A, Tinto H, et al. Safety and efficacy of malaria vaccine candidate R21/Matrix-
474 M in African children: a multicentre, double-blind, randomised, phase 3 trial. *Lancet* 2024; **403**(10426):
475 533-44.
- 476 4. Draper SJ, Sack BK, King CR, et al. Malaria Vaccines: Recent Advances and New Horizons. *Cell*
477 *Host Microbe* 2018; **24**(1): 43-56.
- 478 5. Sirima SB, Mordmuller B, Milligan P, et al. A phase 2b randomized, controlled trial of the
479 efficacy of the GMZ2 malaria vaccine in African children. *Vaccine* 2016; **34**(38): 4536-42.
- 480 6. Thera MA, Doumbo OK, Coulibaly D, et al. A field trial to assess a blood-stage malaria vaccine.
481 *N Engl J Med* 2011; **365**(11): 1004-13.
- 482 7. Sagara I, Dicko A, Ellis RD, et al. A randomized controlled phase 2 trial of the blood stage
483 AMA1-C1/Alhydrogel malaria vaccine in children in Mali. *Vaccine* 2009; **27**(23): 3090-8.
- 484 8. Ogutu BR, Apollo OJ, McKinney D, et al. Blood stage malaria vaccine eliciting high antigen-
485 specific antibody concentrations confers no protection to young children in Western Kenya. *PLoS ONE*
486 2009; **4**(3): e4708.
- 487 9. Genton B, Betuela I, Felger I, et al. A recombinant blood-stage malaria vaccine reduces
488 *Plasmodium falciparum* density and exerts selective pressure on parasite populations in a phase 1-2b trial
489 in Papua New Guinea. *J Infect Dis* 2002; **185**(6): 820-7.
- 490 10. Douglas AD, Williams AR, Illingworth JJ, et al. The blood-stage malaria antigen PfRH5 is
491 susceptible to vaccine-inducible cross-strain neutralizing antibody. *Nat Commun* 2011; **2**: 601.
- 492 11. Crosnier C, Bustamante LY, Bartholdson SJ, et al. Basigin is a receptor essential for erythrocyte
493 invasion by *Plasmodium falciparum*. *Nature* 2011; **480**(7378): 534-7.
- 494 12. Galaway F, Yu R, Constantinou A, Prugnolle F, Wright GJ. Resurrection of the ancestral RH5
495 invasion ligand provides a molecular explanation for the origin of *P. falciparum* malaria in humans. *PLoS*
496 *Biol* 2019; **17**(10): e3000490.
- 497 13. Douglas AD, Baldeviano GC, Lucas CM, et al. A PfRH5-Based Vaccine Is Efficacious against
498 Heterologous Strain Blood-Stage *Plasmodium falciparum* Infection in Aotus Monkeys. *Cell Host*
499 *Microbe* 2015; **17**(1): 130-9.
- 500 14. Minassian AM, Silk SE, Barrett JR, et al. Reduced blood-stage malaria growth and immune
501 correlates in humans following RH5 vaccination. *Med* 2021; **2**(6): 701-19.
- 502 15. Douglas AD, Baldeviano GC, Jin J, et al. A defined mechanistic correlate of protection against
503 *Plasmodium falciparum* malaria in non-human primates. *Nat Commun* 2019; **10**(1): 1953.
- 504 16. Payne RO, Silk SE, Elias SC, et al. Human vaccination against RH5 induces neutralizing
505 antimalarial antibodies that inhibit RH5 invasion complex interactions. *JCI Insight* 2017; **2**(21): 96381.
- 506 17. Silk SE, Kalinga WF, Mtaka IM, et al. Superior antibody immunogenicity of a viral-vectored
507 RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults. *Med* 2023; **4**(10): 668-86.
- 508 18. Silk SE, Kalinga WF, Salkeld J, et al. Blood-stage malaria vaccine candidate RH5.1/Matrix-M in
509 healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre,
510 phase 1b trial. *Lancet Infect Dis* 2024; **24**(10): 1105-17.
- 511 19. Jin J, Tarrant RD, Bolam EJ, et al. Production, quality control, stability, and potency of cGMP-
512 produced *Plasmodium falciparum* RH5.1 protein vaccine expressed in *Drosophila* S2 cells. *NPJ Vaccines*
513 2018; **3**: 32.
- 514 20. Malkin EM, Diemert DJ, McArthur JH, et al. Phase 1 clinical trial of apical membrane antigen 1:
515 an asexual blood-stage vaccine for *Plasmodium falciparum* malaria. *Infect Immun* 2005; **73**(6): 3677-85.

- 516 21. Heath PT, Galiza EP, Baxter DN, et al. Safety and Efficacy of NVX-CoV2373 Covid-19
517 Vaccine. *N Engl J Med* 2021; **385**(13): 1172-83.
- 518 22. Chandramohan D, Zongo I, Sagara I, et al. Seasonal Malaria Vaccination with or without
519 Seasonal Malaria Chemoprevention. *N Engl J Med* 2021; **385**(11): 1005-17.
- 520 23. Regules JA, Cicitelli SB, Bennett JW, et al. Fractional Third and Fourth Dose of RTS,S/AS01
521 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and
522 Immunogenicity Study. *J Infect Dis* 2016; **214**(5): 762-71.
- 523 24. Samuels AM, Ansong D, Kariuki SK, et al. Efficacy of RTS,S/AS01(E) malaria vaccine
524 administered according to different full, fractional, and delayed third or early fourth dose regimens in
525 children aged 5-17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial.
526 *Lancet Infect Dis* 2022; **22**(9): 1329-42.
- 527 25. Osier FH, Mackinnon MJ, Crosnier C, et al. New antigens for a multicomponent blood-stage
528 malaria vaccine. *Sci Transl Med* 2014; **6**(247): 247ra102.
529

530 **Figure Legends**

531 **Figure 1: Trial profile.**

532 Participants allocated to the delayed regimen received vaccinations at 0-1-5 months. Participants allocated
533 to the monthly regimen received vaccinations at 0-1-2 months. Participants were aged 5-17 months at
534 enrolment (first day of vaccination). MM = Matrix-M.

535

536 **Table 1: Analysis of time to first episode of clinical malaria from 14 days to 6 months post-**
537 **third vaccination.**

538 Cox regression models were used to analyse the primary endpoint of time to first episode of clinical
539 malaria based on the per-protocol population at the 6-month analysis timepoint. Clinical malaria is
540 defined as measured axillary temperature $\geq 37.5^{\circ}\text{C}$ and/or reported history of fever within the last 24
541 hours, and *P. falciparum* asexual parasitaemia concentration according to each case definition. Vaccine
542 Efficacy = 1 – hazard ratio. 95% CI = 95% Confidence Interval. * Secondary analysis adjusted vaccine
543 efficacy: includes covariates of total number of rounds of SMC received, ITN use (adequate or not) the
544 night before the screening visit, and age categories 5-8 months, 9-12 months, 13-17 months. Excludes 5
545 children with missing data on covariates: 1 in the Delayed Rabies arm, 3 in the Delayed RH5.1/Matrix-M
546 arm and 1 in the Monthly RH5.1/Matrix-M arm. ** Event rate per 100 days (where event is the first
547 episode of clinical malaria) is also reported for information only, calculated as: (the number of events /
548 [child days/100]).

549

550 **Figure 2: Kaplan-Meier curves showing time to first episode of clinical malaria from 14**
551 **days to 6 months post-third vaccination.**

552 The primary analysis was based on the per-protocol population. (A) Primary case definition of clinical
553 malaria with parasitaemia >5000 parasites/ μL . (B) Secondary case definition of clinical malaria with

554 parasitaemia >0 parasites/ μ L, or (C) >20,000 parasites/ μ L. (D) Additional case definition of clinical
555 malaria with parasitaemia >50,000 parasites/ μ L, or (E) >100,000 parasites/ μ L.

556

557 **Table 2: Solicited AEs within 7 days of vaccine dose across all groups.**


558 By number of doses (n and (%)). Includes all children in the intention-to-treat sample who received at
559 least one dose of vaccine. N = number of participants who received each dose.

560

561 **Figure 3: RH5.1/Matrix-M humoral immunogenicity.**

562 Immunological outcomes in study participants in the per-protocol sample. (A) Anti-RH5.1 serum IgG
563 responses by vaccination group at baseline (screening) and day 14 post-vaccine dose three. Individual
564 anti-RH5.1 total IgG antibody concentrations (dots) and geometric mean with 95% CIs (diamonds with
565 black bars). N=111 children for the Rabies (Rabivax-S) delayed and monthly groups combined, N=113
566 for the Delayed RH5.1/Matrix-M group, and N=107 for the Monthly RH5.1/Matrix-M group. (B)
567 Percentage *in vitro* GIA of 3D7 clone *P. falciparum* parasites by vaccination group, using 2.5mg/mL total
568 IgG purified from serum taken on day 14 post-vaccine dose three. Individual percentage inhibition figures
569 (small dots) and median and interquartile range (large dots and black bars). N=97 children for the Rabies
570 (Rabivax-S) delayed and monthly groups combined, N=113 children for the Delayed RH5.1/Matrix-M
571 group, and N=108 for the Monthly RH5.1/Matrix-M group.

Figure 1: Trial profile




medRxiv preprint doi: <https://doi.org/10.1101/2024.10.15.24315473>; this version posted October 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Table 1: Analysis of time to first episode of clinical malaria from 14 days to 6 months post-third vaccination.

Groups	N	Event rate per 100 days **	VACCINE EFFICACY (95% CI)	p	VACCINE EFFICACY (95% CI) [adjusted*]	p [adjusted]
Primary Case Definition (parasitaemia >5000 parasites/μL)						
Rabies controls (combined)	112	0.21 (33/156.3)	1		1	
Delayed RH5.1/Matrix-M	114	0.09 (17/185.0)	0.55 (0.20, 0.75)	0.0071	0.57 (0.23, 0.77)	0.0051
Monthly RH5.1/Matrix-M	112	0.12 (22/176.4)	0.40 (-0.03, 0.65)	0.0657	0.42 (-0.01, 0.66)	0.0525
Secondary Case Definition (parasitaemia >0 parasites/μL)						
Rabies controls (combined)	112	0.26 (39/147.4)	1		1	
Delayed RH5.1/Matrix-M	114	0.15 (26/176.5)	0.44 (0.08, 0.66)	0.0226	0.44 (0.06, 0.66)	0.0283
Monthly RH5.1/Matrix-M	112	0.25 (39/158.9)	0.08 (-0.44, 0.41)	0.7280	0.07 (-0.46, 0.41)	0.7489
Secondary Case Definition (parasitaemia >20,000 parasites/μL)						
Rabies controls (combined)	112	0.17 (28/164.3)	1		1	
Delayed RH5.1/Matrix-M	114	0.05 (10/194.5)	0.69 (0.35, 0.85)	0.0017	0.68 (0.33, 0.85)	0.0024
Monthly RH5.1/Matrix-M	112	0.09 (16/183.0)	0.47 (0.03, 0.71)	0.0410	0.52 (0.12, 0.74)	0.0186
Additional Case Definition (parasitaemia >50,000 parasites/μL)						
Rabies controls (combined)	112	0.11 (19/178.7)	1		1	
Delayed RH5.1/Matrix-M	114	0.02 (4/203.4)	0.81 (0.44, 0.94)	0.0026	0.79 (0.38, 0.93)	0.0047
Monthly RH5.1/Matrix-M	112	0.01 (2/201.9)	0.90 (0.58, 0.98)	0.0017	0.91 (0.62, 0.98)	0.0011
Additional Case Definition (parasitaemia >100,000 parasites/μL)						
Rabies controls (combined)	112	0.06 (11/190.2)	1		1	
Delayed RH5.1/Matrix-M	114	0.01 (2/206.3)	0.83 (0.23, 0.96)	0.0213	0.82 (0.18, 0.96)	0.0271
Monthly RH5.1/Matrix-M	112	0.00 (1/203.1)	0.91 (0.33, 0.99)	0.0193	0.92 (0.39, 0.99)	0.0148

medRxiv preprint doi: <https://doi.org/10.1101/2024.10.15.24315473>; this version posted October 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 2: Kaplan-Meier curves showing time to first episode of clinical malaria from 14 days to 6 months post-third vaccination.



medRxiv preprint doi: <https://doi.org/10.1101/2024.10.15.24315473>; this version posted October 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Table 2: Solicited AEs within 7 days of vaccine dose across all groups.

Adverse event	Dose number	Delayed Rabies Control	Delayed RH5.1/Matrix-M	Monthly Rabies Control	Monthly RH5.1/Matrix-M
N	Dose 1	62	119	60	120
N	Dose 2	61	118	60	119
N	Dose 3	55	114	57	113
Local events					
Pain	Dose 1	3 (5·0)	5 (4·2)	1 (1·7)	0 (0·0)
	Dose 2	1 (1·6)	6 (5·1)	0 (0·0)	1 (0·8)
	Dose 3	0 (0·0)	3 (2·6)	1 (1·8)	3 (2·7)
Swelling	Dose 1	1 (1·6)	0 (0·0)	0 (0·0)	0 (0·0)
	Dose 2	0 (0·0)	17 (14·4)	1 (1·7)	5 (4·2)
	Dose 3	0 (0·0)	2 (1·8)	0 (0·0)	0 (0·0)
Redness	Dose 1	0 (0·0)	0 (0·0)	1 (1·7)	0 (0·0)
	Dose 2	0 (0·0)	1 (0·8)	0 (0·0)	2 (1·7)
	Dose 3	0 (0·0)	0 (0·0)	0 (0·0)	0 (0·0)
Warmth	Dose 1	2 (3·2)	3 (2·5)	0 (0·0)	0 (0·0)
	Dose 2	0 (0·0)	2 (1·7)	0 (0·0)	4 (3·4)
	Dose 3	1 (1·8)	1 (0·9)	0 (0·0)	1 (0·9)
Systemic events					
Fever	Dose 1	1 (1·6)	6 (5·0)	0 (0·0)	4 (3·3)
	Dose 2	2 (3·3)	27 (22·9)	1 (1·7)	26 (21·8)
	Dose 3	1 (1·8)	21 (18·4)	0 (0·0)	13 (11·5)
Irritable	Dose 1	0 (0·0)	0 (0·0)	0 (0·0)	0 (0·0)
	Dose 2	1 (1·6)	2 (1·7)	1 (1·7)	0 (0·0)
	Dose 3	1 (1·8)	1 (0·9)	1 (1·8)	1 (0·9)
Drowsiness	Dose 1	0 (0·0)	4 (3·4)	1 (1·7)	0 (0·0)
	Dose 2	0 (0·0)	3 (2·5)	0 (0·0)	1 (0·8)
	Dose 3	0 (0·0)	0 (0·0)	0 (0·0)	1 (0·9)
Loss of appetite	Dose 1	1 (1·6)	2 (1·7)	0 (0·0)	0 (0·0)
	Dose 2	2 (3·3)	4 (3·4)	1 (1·7)	1 (0·8)
	Dose 3	1 (1·8)	1 (0·9)	0 (0·0)	1 (0·9)

medRxiv preprint doi: <https://doi.org/10.1101/2024.10.15.24315473>; this version posted October 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 3: RH5.1/Matrix-M humoral immunogenicity.

